Skip to content

Comparison of Clinical Outcomes between RARP and ThuLEP for Treating Extremely Large Prostates: A Single-center Randomized Controlled Trial

Comparison of Clinical Outcomes between RARP and ThuLEP for Treating Extremely Large Prostates: A Single-center Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117785
Enrollment
Unknown
Registered
2026-01-28
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Interventions

RARP Group:Using the RARP surgical approach, specimens were sent for pathological examination postoperatively.
ThuLEP Group:Under urethral laser enucleation of the prostate

Sponsors

The Second Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Patients with PSA levels below 4ng/ml, or those whose imaging data do not suggest suspicious cancer nodules or the possibility of prostate cancer; 2. Patients with prostate volume greater than 80ml as indicated by preoperative ultrasound or MRI; 3. Patients with a life expectancy greater than 10 years; 4. Patients who can tolerate general anesthesia as assessed by anesthesiologists.

Exclusion criteria

Exclusion criteria: 1. Patients with a life expectancy less than 10 years or who cannot tolerate surgical treatment. 2. Patients who cannot complete prostate-related imaging examinations. 3. Patients who have high requirements for functional preservation, such as sexual function and urinary control, and cannot accept surgical complications. 4. Patients with urodynamic examination results or other evidence suggesting possible neurogenic bladder. 5. Patients with prostate malignancy.

Design outcomes

Primary

MeasureTime frame
Operation time;Operative blood loss;Prostate Tissue Clearance Rate;Duration of hospitalization;

Secondary

MeasureTime frame
Maximum urinary flow rate (Qmax);Residual Urine in Bladder;IPSS(QoL);IIEF-5 Form;Urinary Incontinence (Pad Test);

Countries

China

Contacts

Public ContactLiu Xiaolong

The Second Affiliated Hospital of Soochow University

liuxiaolong2005@suda.edu.cn+86 138 1485 0558

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026